Jeremie Guedj

Citée par

	Toutes	Depuis 2020
Citations	9375	6463
indice h	53	39
indice i10	120	95

1600

800

400

1200

2009201020112012201320142015201620172018201920202021202220232024202530 29 75 106 203 316 356 335 438 469 405 790 1219 1584 1417 1282 131

Accès public

Tout afficher

117 articles

3 articles

disponibles

non disponibles

Sur la base des exigences liées au financement

Coauteurs

Pr France MentrePr of Biostatistics, University Paris DiderotAdresse e-mail validée de inserm.fr
Alan S PerelsonSenior Fellow, Los Alamos National LaboratoryAdresse e-mail validée de lanl.gov
Harel DahariAssociate Professor, PhD, Loyola University Chicago Medical CenterAdresse e-mail validée de luc.edu
Rodolphe ThiébautUniversité de bordeauxAdresse e-mail validée de u-bordeaux.fr
Daniel CommengesINSERM Researcher, Univ BordeauxAdresse e-mail validée de isped.u-bordeaux2.fr
Cédric LaouénanUniversité Paris Cité, AP-HP, Inserm IAME UMR 1137 & CIC-EC 1425Adresse e-mail validée de inserm.fr
Guillaume LingasAdresse e-mail validée de inserm.fr
Julie BertrandINSERMAdresse e-mail validée de inserm.fr
Charles BurdetInserm UMR 1137 "IAME". Infection. Antimicrobials. Modeling. EvolutionAdresse e-mail validée de inserm.fr
Libin RongProfessor of Mathematics, University of FloridaAdresse e-mail validée de ufl.edu
Susan L. UprichardLoyola University Chicago Medical CenterAdresse e-mail validée de luc.edu
Franck TouretUnité des virus émérgentsAdresse e-mail validée de univ-amu.fr
Lisa OestereichBernhard Nocht Institute for Tropical MedicineAdresse e-mail validée de bnitm.de
Micha LeviGates MRIAdresse e-mail validée de gatesmri.org
Francois MercierF. Hoffmann-La RocheAdresse e-mail validée de roche.com
François BlanquartCNRSAdresse e-mail validée de college-de-france.fr
Andrés PizzornoCentre International de Recherche en Infectiologie (CIRI) - Team VirPath, Lyon, FranceAdresse e-mail validée de univ-lyon1.fr
Olivier TerrierVirPath Team, Centre international de Recherche en Infectiologie (CIRI), INSERM U1111 UMR CNRS 5308Adresse e-mail validée de univ-lyon1.fr
Emmanuelle CometsINSERM (National Institute of Health and Medical Research, France)Adresse e-mail validée de inserm.fr
Melanie PragueFaculty Researchor - Inria, Inserm Bordeaux Population Health U1219, ISPED, Université BordeauxAdresse e-mail validée de inria.fr

Suivre

Jeremie Guedj

Researcher at the French Institute of Health and Medical Research (INSERM)

Adresse e-mail validée de inserm.fr - Page d'accueil

infectious diseases pharmacometrics viral dynamics antivirals


Titre Trier par citations Trier par année Trier par titre	Citée par Citée par	Année
Experimental treatment with favipiravir for Ebola virus disease (the JIKI Trial): a historically controlled, single-arm proof-of-concept trial in Guinea D Sissoko, C Laouenan, E Folkesson, AB M’lebing, AH Beavogui, S Baize, ... PLoS medicine 13 (3), e1001967, 2016	602	2016
Autoantibodies neutralizing type I IFNs are present in~ 4% of uninfected individuals over 70 years old and account for~ 20% of COVID-19 deaths P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, J Manry, ... Science immunology 6 (62), eabl4340, 2021	540	2021
Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life J Guedj, H Dahari, L Rong, ND Sansone, RE Nettles, SJ Cotler, ... Proceedings of the National Academy of Sciences 110 (10), 3991-3996, 2013	423	2013
Hydroxychloroquine use against SARS-CoV-2 infection in non-human primates P Maisonnasse, J Guedj, V Contreras, S Behillil, C Solas, R Marlin, ... Nature 585 (7826), 584-587, 2020	400	2020
Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled … F Ader, M Bouscambert-Duchamp, M Hites, N Peiffer-Smadja, J Poissy, ... The Lancet infectious diseases 22 (2), 209-221, 2022	393	2022
X-linked recessive TLR7 deficiency in~ 1% of men under 60 years old with life-threatening COVID-19 T Asano, B Boisson, F Onodi, D Matuozzo, M Moncada-Velez, ... Science immunology 6 (62), eabl4348, 2021	385	2021
Timing of antiviral treatment initiation is critical to reduce SARS‐CoV‐2 viral load A Gonçalves, J Bertrand, R Ke, E Comets, X De Lamballerie, D Malvy, ... CPT: pharmacometrics & systems pharmacology 9 (9), 509-514, 2020	238	2020
Modeling SARS-CoV-2 viral kinetics and association with mortality in hospitalized patients from the French COVID cohort N Néant, G Lingas, Q Le Hingrat, J Ghosn, I Engelmann, Q Lepiller, ... Proceedings of the National Academy of Sciences 118 (8), e2017962118, 2021	225	2021
Ebola virus infection: review of the pharmacokinetic and pharmacodynamic properties of drugs considered for testing in human efficacy trials V Madelain, THT Nguyen, A Olivo, X De Lamballerie, J Guedj, AM Taburet, ... Clinical pharmacokinetics 55 (8), 907-923, 2016	216	2016
Quantifying the diversification of hepatitis C virus (HCV) during primary infection: estimates of the in vivo mutation rate RM Ribeiro, H Li, S Wang, MB Stoddard, GH Learn, BT Korber, ... Public Library of Science 8 (8), e1002881, 2012	197	2012
Favipiravir pharmacokinetics in Ebola-Infected patients of the JIKI trial reveals concentrations lower than targeted THT Nguyen, J Guedj, X Anglaret, C Laouénan, V Madelain, AM Taburet, ... PLoS neglected tropical diseases 11 (2), e0005389, 2017	191	2017
The risk of COVID-19 death is much greater and age dependent with type I IFN autoantibodies J Manry, P Bastard, A Gervais, T Le Voyer, J Rosain, Q Philippot, ... Proceedings of the National Academy of Sciences 119 (21), 2022	164	2022
Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model JS Driouich, M Cochin, G Lingas, G Moureau, F Touret, PR Petit, ... Nature communications 12 (1), 1735, 2021	152	2021
Persistence and clearance of Ebola virus RNA from seminal fluid of Ebola virus disease survivors: a longitudinal analysis and modelling study D Sissoko, S Duraffour, R Kerber, JS Kolie, AH Beavogui, AM Camara, ... The Lancet Global Health 5 (1), e80-e88, 2017	146	2017
Viral dynamics in patients with monkeypox infection: a prospective cohort study in Spain C Suñer, M Ubals, EJ Tarín-Vicente, A Mendoza, A Alemany, ... The Lancet Infectious Diseases 23 (4), 445-453, 2023	139	2023
Quantifying the relationship between SARS-CoV-2 viral load and infectiousness A Marc, M Kerioui, F Blanquart, J Bertrand, O Mitja, M Corbacho-Monné, ... Elife 10, e69302, 2021	138	2021
Dose regimen of favipiravir for Ebola virus disease. F Mentré, AM Taburet, J Guedj, X Anglaret, S Keïta, X Lamballerie, ...	138	2015
Antiviral efficacy of favipiravir against Ebola virus: A translational study in cynomolgus macaques J Guedj, G Piorkowski, F Jacquot, V Madelain, THT Nguyen, A Rodallec, ... PLoS medicine 15 (3), e1002535, 2018	137	2018
Second‐phase hepatitis C virus RNA decline during telaprevir‐based therapy increases with drug effectiveness: implications for treatment duration J Guedj, AS Perelson Hepatology 53 (6), 1801-1808, 2011	129	2011
Analysis of hepatitis C virus decline during treatment with the protease inhibitor danoprevir using a multiscale model L Rong, J Guedj, H Dahari, DJ Coffield Jr, M Levi, P Smith, AS Perelson PLoS computational biology 9 (3), e1002959, 2013	123	2013

Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.

Articles 1–20

Nombre de citations par an

Citations en double

Citations fusionnées

Ajouter les coauteursCoauteurs

Suivre

Citée par

Coauteurs